The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

View the full release here: "I'm excited to welcome Alastair to Chemify to help us with building and scaling our ability to ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

The U.S. 2nd Court of Appeals recently revisited a whistleblower lawsuit against Novartis, a Swiss pharmaceutical company, creating a new development in the enforcement of the Anti-Kickback Statute, ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...